New tozorakimab data strengthen the case for treating a broader COPD population. A credible launch forecast must separately model eligibility, identification, funded assessment and sustained treatment.
WEEK OF 27 JULY–2 AUGUST 2026 · 14-MINUTE READ Reported performance tells you what happened. Reallocation tells you what the organisation believes will matter next. Last week’s signal argued that the route through which science reaches the market has become part of the strategy. This week showed what leaders must move to build that route….
Week of 13–19 July 2026 · 11-minute read What companies source matters. What their operating model can convert matters more. Last week’s signal asked who industrialises the science. This week, the buyers answered. AstraZeneca licensed a lung-cancer medicine discovered in China. Angelini Pharma completed a $4.1 billion acquisition that gives it a US rare-disease portfolio…
Week of 18–24 May 2026 This week looked fragmented at first glance: a US approval for a hypertension medicine, Veeva’s commercial software summit, CHMP opinions on oral Wegovy and biomarker-led oncology, EUDAMED’s approaching deadline, and EMA’s breakthrough device pilot closing its first application window. They are not fragmented. The common thread is upstream commercial design….
Week of 11–17 May 2026 The procedural week was supposed to be quiet. It was anything but. Bristol Myers Squibb committed up to $15.2 billion to Hengrui across 13 early-stage programmes. Roche bought deeper into AI diagnostics. Bayer’s Q1 numbers showed the commercial cost of patent-cliff transition in plain sight. NICE recommended AstraZeneca’s Imfinzi for…
Week of 27 April–3 May 2026 Europe had a useful reality check this week. The strongest signals did not come from glossy AI claims, minor partnerships dressed up as strategy, or another ceremonial innovation slogan. They came from the machinery beneath growth: pricing, launch sequencing, regulatory support, evidence expectations, operating-model discipline, and whether Europe can…